Betacap TR40 mg

Betacap TR 40 mg is indicated for: Essential hypertension, Angina pectoris, Cardiac arrhythmia, Thyrotoxicosis, Anxiety, and Prophylaxis of migraine, among other conditions.

Beta-adrenoceptor blocking drugs, Beta-blockers

Betacap TR 40 mg is a non-cardioselective β-blocker that competitively blocks β1- and β2-receptors, leading to reduced heart rate, myocardial contractility, blood pressure, and myocardial oxygen demand. It also possesses membrane-stabilizing properties.

Tablet: 
- Adults: Hypertension: A starting dose of 80 mg twice a day may be increased at weekly intervals according to response. The usual dose range is 160-320 mg per day. When used concurrently with diuretics or other antihypertensive drugs, further reduction of blood pressure is achieved. 
- Angina, anxiety, migraine, and essential tremor: A starting dose of 40 mg two or three times daily may be increased by the same amount at weekly intervals according to the patient's response. An adequate response in anxiety, migraine, and essential tremor is typically seen in the range of 80-160 mg/day, and for angina, in the range of 120-240 mg/day. 
- Situational and generalized anxiety: A dose of 40 mg daily may provide short-term relief of acute situational anxiety. Generalized anxiety usually responds well to 40 mg twice daily, and in individual cases, this may be increased to 40 mg three times daily. Treatment should be continued based on responses, with patient reviews after 6 to 12 months of treatment. 
- Dysrhythmias, anxiety tachycardia, hypertrophic obstructive cardiomyopathy, and thyrotoxicosis: A dosage range of 10-40 mg three or four times a day usually achieves the required response. 
- Post myocardial infarction: Treatment should begin between days 5 and 21 after myocardial infarction, with an initial dose of 40 mg four times a day for 2 or 3 days. To improve compliance, the total daily doses should be given as 80 mg twice a day. 
- Phaeochromocytoma (Used only with an alpha receptor blocking drug): Pre-operative: 60 mg daily for three days. Non-operable malignant cases: 30 mg daily. 
- Migraine: Under 12 years: 20 mg two or three times daily. Over 12 years: The adult dose. 
- Children: Dysrhythmias, Phaeochromocytoma, Thyrotoxicosis: Dosage should be individually determined, with the following serving as a guide: 0.25-0.5 mg/kg three or four times daily as required.

Sustained Release Capsule: 
- Adult: Hypertension: The usual initial dose is 80 mg of Propranolol SR once daily, whether used alone or in combination with a diuretic. The usual maintenance dosage is 120 to 160 mg once daily. 
- Angina pectoris: Starting with 80 mg of Propranolol SR once daily, the dosage should be gradually increased at three to seven-day intervals until the optimum response is achieved. 
- Migraine: The initial oral dose is 80 mg of Propranolol SR once daily. The usual effective dose range is 160 to 240 mg once daily. Gradual withdrawal of the drug over several weeks may be advisable in some cases. 
- Hypertrophic subaortic stenosis: 80 mg of Propranolol SR once daily.

Injection: 
- Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever the solution and container permit. The usual dose is 1 to 3 mg administered under careful monitoring, such as electrocardiography and central venous pressure. The rate of administration should not exceed 1 mg (1 mL) per minute to minimize the possibility of lowering blood pressure and causing cardiac standstill. 
- Sufficient time should be allowed for the drug to reach the site of action, even when a slow circulation is present. If necessary, a second dose may be given after two minutes. Additional drug should not be administered in less than four hours after that. 
- Additional Betacap TR 40 mg should not be given when the desired alteration in rate or rhythm is achieved. Transfer to oral therapy as soon as possible.

Patients receiving verapamil, salbutamol, levosalbutamol, ergot alkaloids, lidocaine, or phenobarbital drugs should be closely observed during therapy.

Bronchospasm, cardiogenic shock, second or third degree heart block, diabetes mellitus etc.

Cold extremities, lassitude, nausea, dizziness, insomnia, paresthesia etc.

There are no sufficient and controlled studies in pregnant women. Betacap TR 40 mg is excreted in human milk. Caution should be taken when administering propranolol to a nursing mother.

It should be used cautiously in cases of hepatic and renal impairment, during pregnancy, and while breastfeeding.

Symptoms of overdose may encompass bradycardia, hypotension, acute cardiac insufficiency, and bronchospasm. Overdose treatment involves close monitoring, care in an intensive care unit, gastric lavage, activated charcoal, and a laxative to hinder drug absorption in the gastrointestinal tract. Additionally, plasma or plasma substitutes may be employed to address hypotension and shock.

Store in a cool and dry place, protected from light.

Beta-adrenoceptor blocking drugs, Beta-blockers

Betacap TR 40 mg is a β-adrenergic receptor-blocking medication widely used for treating hypertension and angina pectoris. It works by antagonizing catecholamines at β-adrenergic receptors, thus preventing excessive heart rate and force of contraction, and reducing the heart's oxygen consumption.

Propranolol is almost entirely absorbed from the gastrointestinal tract, with a portion undergoing immediate liver metabolism when passing through the portal circulation. Peak plasma concentration is reached within 1 to 1.5 hours after oral administration, with a plasma half-life ranging from 3 to 6 hours. Propranolol's metabolites are excreted through the urine.